Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra™)

HIV Clinical Trials

Volumn 5, Issue 6, 2004, Pages 392-398

  Lafeuillade, Alain ^a   Hittinger, Gilles ^a   Philip, Gisèle ^a   Lambry, Véronique ^a   Jolly, Patricia ^a   Poggi, Cécile ^a  

^a Hopital Chalucet Toulon   (France)

Author keywords

Adverse effects; Cholesterol; Cohort; HIV; Lipids; Lopinavir; Metabolism; Protease inhibitor; Triglycerides

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NORMAL VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; INSULIN; MALE; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; TRIGLYCERIDES;

EID: 13844297903     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/Q0TG-0V50-9JML-638U     Document Type: Article

References (23)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
2. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;1:10-14.
3. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;7:1695-1700.
4. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
5. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
6. Hicks C, King M, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775-779.
7. Clevenbergh P, Garraffo R, Dellamonica P. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clin Trials. 2003;5:330-336.
8. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;17:179-183.
9. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-1931.
10. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
11. Grunfeld Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr. 2000;25(suppl 1):S4-11.
12. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
13. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV infected individuals treated with protease inhibitors. The Swiss Cohort Study. Circulation. 1999;100:700-705.
14. Thiébaut R, Dabis F, Malvy D, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr. 2000;23:261-265.
15. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185(5):599-607.
16. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174.
17. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004;38:1017-1023.
18. Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavar/ritonavir. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 714.
19. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2003;33:544-546.
20. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
21. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004;23:625-630.
22. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS. 2003;17:443-445.
23. Noor MA, Mulvey R, Wang S, et al. Maintenance of favorable in vitro metabolic profile of atazanavir when combined with low dose ritonavir. IAS. 2004;11:1. (electronic journal)